SCHEMBL13201507

SCHEMBL13201507

Cc1nc2ccc(-c3nn(C)c4ncnc(N)c34)cc2[nH]1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 17/20 0.65
PIK3CA P42336 17/20 0.65
PIK3CB P42338 17/20 0.65
PIK3CG P48736 17/20 0.65
PRKDC P78527 17/20 0.65
ABL1 P00519 15/20 0.65
EGFR P00533 15/20 0.65
HCK P08631 15/20 0.65
SRC P12931 15/20 0.65
MTOR P42345 15/20 0.65
EPHB4 P54760 15/20 0.65
KDR P35968 14/20 0.65
PI4KB Q9UBF8 2/20 0.60
NUDT14 O95848 1/20 0.51
NUDT5 Q9UKK9 1/20 0.51
RET P07949 1/20 0.50
AURKA O14965 1/20 0.47
IKBKE Q14164 1/20 0.47
AURKB Q96GD4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130528 0.91 PIK3CD (0.62) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL13201514 0.86 PIK3CD (0.62) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL16655801 0.80 PIK3CD (0.66) PIK3CDEGFR
SCHEMBL130423 0.79 PIK3CD (1.00) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL12162 0.78 PIK3CD (0.74) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL130513 0.78 SRC (0.79) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL13828403 0.77 BMPR1B (0.64) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL129811 0.77 PIK3CD (0.63) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL129501 0.77 PIK3CD (0.65) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL23997199 0.77 SRC (0.73) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 US disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 PIK3CD 264/4885PIK3CA 139/4885PIK3CB 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.